Home › Cancro al fegato (carcinoma epatocellulare) › Pennsylvania › Pittsburgh
Studi clinici su Cancro al fegato (carcinoma epatocellulare) a Pittsburgh, PA
15 studi su Cancro al fegato (carcinoma epatocellulare) cercano partecipanti presso sedi a Pittsburgh e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Phase 1 Study of the Safety and Tolerability of CTX-10726
In reclutamentoFase 1
- UPMC Hillman Cancer Center, Pittsburgh
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
In reclutamentoFase 1
- Exelixis Clinical Site #32, Pittsburgh
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
In reclutamentoFase 1/2
- Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
In reclutamentoFase 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
In reclutamentoFase 3
- Research Site, Pittsburgh
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
In reclutamentoFase 1/2
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
FOG-001 in Locally Advanced or Metastatic Solid Tumors
In reclutamentoFase 1/2
- University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh
Molecular Basis of Pediatric Liver Cancer
In reclutamentoStudio osservazionale
- UPMC Children's Hospital of Pittsburgh, Pittsburgh
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
In reclutamentoFase 2
- Allegheny General Hospital, Pittsburgh
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
In reclutamentoFase 2
- UPMC Hillman Cancer Center, Pittsburgh
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
In reclutamentoFase 1
- Clinical Trial Site, Pittsburgh
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
In reclutamentoFase 2
- UPMC Hillman Cancer Center, Pittsburgh
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
In reclutamentoFase 2
- UPMC Hillman Cancer Center, Pittsburgh
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
In reclutamentoFase 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
In reclutamentoFase 2
- UPMC Hillman Cancer Center, Pittsburgh
Studi su Cancro al fegato (carcinoma epatocellulare) in altre città
- Houston, TX31 studi
- New York City, NY24 studi
- Dallas, TX19 studi
- Los Angeles, CA19 studi
- Boston, MA18 studi
- Cleveland, OH18 studi
- Chicago, IL16 studi
- Philadelphia, PA16 studi
- San Francisco, CA14 studi
- Orange, CA14 studi
- Jacksonville, FL14 studi
- San Antonio, TX13 studi
Altri studi a Pittsburgh
- Cancro del polmone non a piccole cellule48 studi
- Cancro (tutti i tipi)41 studi
- Cancro al seno39 studi
- Cancro colorettale32 studi
- Cancro metastatico31 studi
- Melanoma31 studi
- Cancro ovarico30 studi
- Cancro dell'endometrio23 studi
- Cancro alla prostata23 studi
- Cancro ai polmoni23 studi
- Carcinoma a cellule squamose della testa e del collo22 studi
- Ictus22 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.